WO2025057112 - BUPIVACAINE LIQUID FORMULATIONS
National phase entry:
Publication Number
WO/2025/057112
Publication Date
20.03.2025
International Application No.
PCT/IB2024/058897
International Filing Date
12.09.2024
Title **
[English]
BUPIVACAINE LIQUID FORMULATIONS
[French]
FORMULATIONS LIQUIDES DE BUPIVACAÏNE
Applicants **
FRESENIUS KABI AUSTRIA GMBH
Inventors
CRIVARO, Claudio
MASSER, Christian
MANTOURLIAS, Theofanis
Priority Data
18/465,893
12.09.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2056 | |
| EPO | Filing, Examination, Granting | 8735 | |
| Japan | Filing, Examination, Granting | 2230 | |
| South Korea | Filing, Examination, Granting | 2066 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,827
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides a liquid formulation comprising bupivacaine or a pharmaceutically acceptable salt thereof, a method for preparing the formulation, and a product which includes the formulation. The formulation of the invention may include a tonicity agent, and has an initial pH of from about 4.2 to about 4.5. The formulation of the invention is stable and ready-to-administer.[French]
L'invention concerne une formulation liquide comprenant de la bupivacaïne ou un sel pharmaceutiquement acceptable de celle-ci, un procédé de préparation de la formulation, et un produit qui comprend la formulation. La formulation de l'invention peut comprendre un agent de tonicité, et a un pH initial d'environ 4,2 à environ 4,5. La formulation de l'invention est stable et prête à être administrée.